Sitagliptin/Metformin Extended-Release Tablets (Janumet XR) is a commonly used fixed-dose combination preparation for type 2 diabetes mellitus. While effectively controlling blood glucose, patients need to pay special attention to its potential safety risks.
Adverse Reactions of Sitagliptin/Metformin Extended-Release Tablets (Janumet XR)
Gastrointestinal Reactions
Diarrhea, upper respiratory tract infection and headache.
Gastrointestinal adverse reactions are the most common problems encountered by patients, especially prominent in the initial stage of treatment.
Adverse Reactions Associated with Combination Therapy
The risk of hypoglycemia increases significantly when Sitagliptin/Metformin Extended-Release Tablets are used in combination with insulin or insulin secretagogues.
In a study of combination therapy with glimepiride, the incidence of hypoglycemia in the sitagliptin group was 16.4%.
When used in combination with insulin, the incidence of hypoglycemia in the sitagliptin group can reach 15.3%.
Severe Adverse Reactions of Sitagliptin/Metformin Extended-Release Tablets (Janumet XR)
Lactic Acidosis
This is the most severe adverse reaction of metformin, which is rare but potentially fatal.
The main manifestations include malaise, myalgia, respiratory distress, somnolence and abdominal pain.
Laboratory tests may show elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio, and the plasma concentration of metformin is usually > 5 μg/mL.
Acute Pancreatitis
Patients taking sitagliptin may develop acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis.
If pancreatitis is suspected, Sitagliptin/Metformin Extended-Release Tablets should be discontinued immediately and appropriate management should be implemented.
Precautions for Use of Sitagliptin/Metformin Extended-Release Tablets (Janumet XR)
Dosage and Administration Method
Take orally once daily with a meal.
The maximum recommended daily dose is 100 mg sitagliptin combined with 2000 mg metformin extended-release tablets.
The extended-release tablet formulation must not be split, crushed or chewed.
Requirements for Renal Function Monitoring
Renal function should be assessed prior to the initiation of medication.
Use is contraindicated in patients with an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m².
Initiation of medication is not recommended in patients with an eGFR ranging from 30–45 mL/min/1.73 m².
Clinical Monitoring
Long-term use requires monitoring of vitamin B12 levels.
Renal function needs to be re-examined regularly.
Monitor for possible allergic reactions.
Key Points for Patient Education
Take the medication on time and in the prescribed dose; do not adjust the dose without authorization.
Undergo regular re-examinations of renal function and blood parameters.
Report any uncomfortable symptoms promptly.
Understand potential drug interactions.
